Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106737473 | 10673747 | 3 | F | 20160626 | 20160627 | 20141224 | 20160701 | EXP | PHEH2014US024918 | NOVARTIS | 51.74 | YR | F | Y | 0.00000 | 20160701 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106737473 | 10673747 | 1 | PS | GILENYA | FINGOLIMOD HYDROCHLORIDE | 1 | Oral | 0.5 MG, QD | S0063 | 22527 | .5 | MG | CAPSULE | QD | |||||
| 106737473 | 10673747 | 2 | SS | CARBAMAZEPINE. | CARBAMAZEPINE | 1 | Oral | 200 MG, 5QD | 0 | 200 | MG | ||||||||
| 106737473 | 10673747 | 3 | C | GABAPENTIN. | GABAPENTIN | 1 | Oral | 600 MG, TID | U | 0 | 600 | MG | TABLET | TID | |||||
| 106737473 | 10673747 | 4 | C | BACLOFEN. | BACLOFEN | 1 | Oral | 10 MG, TID | U | 0 | 10 | MG | TABLET | TID | |||||
| 106737473 | 10673747 | 5 | C | NUEDEXTA | DEXTROMETHORPHAN HYDROBROMIDEQUINIDINE SULFATE | 1 | Oral | U | 0 | CAPSULE | QD | ||||||||
| 106737473 | 10673747 | 6 | C | HYDROCODONE | HYDROCODONE | 1 | Oral | 1 DF, Q6H | U | 0 | 1 | DF | Q6H |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 106737473 | 10673747 | 1 | Multiple sclerosis |
| 106737473 | 10673747 | 2 | Product used for unknown indication |
| 106737473 | 10673747 | 3 | Product used for unknown indication |
| 106737473 | 10673747 | 4 | Product used for unknown indication |
| 106737473 | 10673747 | 5 | Product used for unknown indication |
| 106737473 | 10673747 | 6 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 106737473 | 10673747 | OT |
| 106737473 | 10673747 | HO |
| 106737473 | 10673747 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 106737473 | 10673747 | Contusion | |
| 106737473 | 10673747 | Dysarthria | |
| 106737473 | 10673747 | Dyspnoea | |
| 106737473 | 10673747 | Gait disturbance | |
| 106737473 | 10673747 | Monoparesis | |
| 106737473 | 10673747 | Muscular weakness | |
| 106737473 | 10673747 | Paraplegia | |
| 106737473 | 10673747 | Pneumonia | |
| 106737473 | 10673747 | Pollakiuria | |
| 106737473 | 10673747 | Pulmonary oedema | |
| 106737473 | 10673747 | Sneezing | |
| 106737473 | 10673747 | Urinary incontinence | |
| 106737473 | 10673747 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |